RALLYBIO CORP (RLYB)

Rallybio Announces Promising RLYB212 and RLYB332 Preclinical Data at the 66th American Society of Hematology Annual Meeting

Rallybio to Initiate RLYB116 Confirmatory Clinical PK/PD Study in Second Quarter 2025

Rallybio Announces Publication of Target-Mediated Drug Disposition Modeling and Simulations Informing the RLYB212 Dosing Regimen in Pregnant Women

Rallybio to Present at the 2024 Evercore ISI HealthCONx Conference

Rallybio to Provide Update on RLYB116 Program, an Innovative Subcutaneously Injected C5 Inhibitor

Rallybio Announces Initiation of Phase 2 Clinical Trial of RLYB212

Rallybio Reports Third Quarter 2024 Financial Results and Provides Business Updates

Rallybio Announces Approval of Clinical Trial Applications for Phase 2 Trial of RLYB212 in Pregnant Women at Higher Risk of Alloimmunization and FNAIT

Data Demonstrating ENPP1 Inhibition as a Therapeutic Approach for Later-onset Hypophosphatasia Presented at the American Society for Bone and Mineral Research 2024 Annual Meeting

Rallybio to Present Results of Epidemiological Analysis Demonstrating FNAIT Risk Across Racially and Ethnically Diverse Populations at the American Society of Human Genetics 2024 Annual Meeting

Rallybio to Present Results of Epidemiological Analysis Demonstrating FNAIT Risk Across Racially and Ethnically Diverse Populations at the NORD Breakthrough Summit

Fierce Names Rallybio to the 2024 Fierce 50 List as an Innovation Honoree

Rallybio Announces Publication of RLYB212 Phase 1 Proof-of-Concept Study Results in Thrombosis and Haemostasis

Rallybio to Present at Upcoming Investor Conferences

RLYB Stock Earnings: Rallybio Misses EPS for Q2 2024

RLYB stock results show that Rallybio missed analyst estimates for earnings per share the second quarter of 2024.

RLYB Stock Earnings: Rallybio Misses EPS for Q2 2024

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Rallybio (NASDAQ:RLYB) just reported results for the second quarter of 2024.Ral...

Rallybio Reports Second Quarter 2024 Financial Results and Provides Business Updates

Rallybio to Present at the 2024 Jones Healthcare Seaside Summit

Rallybio Announces Results of Epidemiological Analysis Demonstrating FNAIT Risk Across Racially and Ethnically Diverse Populations

3 Sorry Biotech Stocks to Sell in May While You Still Can

Morgan Stanley's bullish outlook highlights the need for strategic trimming of underperforming biotech stocks to sell.

3 Biotech Stocks to Sell in May Before They Crash & Burn

Discover essential insights on biotech stocks to sell in May to navigate market volatility and safeguard your investment portfolio.

RLYB Stock Earnings: Rallybio Beats EPS for Q1 2024

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Rallybio (NASDAQ:RLYB) just reported results for the first quarter of 2024.Rall...

RLYB Stock Earnings: Rallybio Beats EPS for Q1 2024

RLYB stock results show that Rallybio beat analyst estimates for earnings per share the first quarter of 2024.

Rallybio Reports First Quarter 2024 Financial Results and Provides Business Updates

Rallybio to Present at the 2024 Citizens JMP Life Sciences Conference

FNAIT Systematic Literature Review and Meta-Analysis Presented at the Academy of Managed Care Pharmacy 2024 Annual Meeting

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday

Friday is here and we're starting the final day of trading this week with a breakdown of the biggest pre-market stock movers this morning!

Thursday Sector Leaders: Drugs, Shipping Stocks